Evaluating only Ro’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Competition.
Key Events Timeline
FOUNDING
Founded as Roman for men's ED/hair loss
PRODUCT LAUNCH
Expanded to Rory (women's health) and Zero (smoking cessation)
FUNDING
Raised $500M at $7B valuation; 1,000+ employees
ACQUISITION ATTEMPT
Acquired Workpath (in-home diagnostics) for $100M
LAYOFF
Laid off 18% of workforce; pharmacy competition intensified
Full Analysis
Free · no account needed
Documented cause
Ro was a direct-to-patient telehealth platform founded in 2017, originally called Roman, targeting men's sexual health and hair loss. It expanded into women's health (Rory) and smoking cessation (Zero), raising $876 million total and reaching a $7 billion valuation in 2021. Two forces destroyed the model: first, GLP-1 drugs (Ozempic, Wegovy) rewrote the obesity treatment market, displacing many conditions Ro treated; second, hims&hers, Amazon, and every major pharmacy scaled up telehealth with larger infrastructure. In 2023, Ro laid off 18% of its workforce and was valued at a fraction of peak.
Lesson
“Raising $876M at $7B creates expectations that require category dominance. When a single drug class (GLP-1s) reshapes your market, being well-capitalized only means you have more runway to lose.”